Medications
Liraglutide vs semaglutide: how Saxenda and Wegovy compare
July 23, 2026 · 2 min read
The short answer
Liraglutide (Saxenda for weight, Victoza for diabetes) and semaglutide (Wegovy for weight, Ozempic and Rybelsus for diabetes) are both GLP-1 receptor agonists, but semaglutide is longer-acting and dosed once weekly while liraglutide is injected once daily.
In trials, semaglutide generally produced greater average weight loss than liraglutide. Both share the same gastrointestinal side-effect profile. The right choice depends on the goal, dosing preference, tolerance, cost, and what a prescriber advises.
The short version
Liraglutide and semaglutide are both GLP-1 receptor agonists, so they work through the same core mechanism: they mimic the GLP-1 hormone to reduce appetite, slow the stomach, and improve blood-sugar control. The practical differences are how often you inject, how much weight loss to expect on average, and the newer options each molecule offers.
The brands
- Liraglutide is sold as Saxenda (weight management) and Victoza (type 2 diabetes). It is a once-daily injection.
- Semaglutide is sold as Wegovy (weight management), Ozempic (type 2 diabetes), and Rybelsus (an oral diabetes tablet). The injectables are once weekly.
Dosing frequency
This is the most obvious difference. Liraglutide (Saxenda, Victoza) is injected once a day, so it needs a daily habit. Semaglutide (Wegovy, Ozempic) is injected once a week because it stays in the body longer. Many people find a weekly injection easier to keep up with, though a daily rhythm suits others. Both are titrated up gradually to limit side effects.
Weight loss
Across their respective trials, semaglutide at weight-management doses generally produced more average weight loss than liraglutide. Liraglutide (Saxenda) still produces meaningful weight loss and has a long track record; it is simply, on average, a less powerful weight-loss tool than semaglutide (Wegovy) in head-to-head and cross-trial terms. Individual results vary widely, and the best drug is the one you tolerate and stay on.
Side effects
The side-effect profiles are very similar because they are the same class: nausea, diarrhea or constipation, and other gut effects are the most common, concentrated during dose increases. Both carry the class thyroid C-cell warning and the same cautions around pancreatitis and gallbladder issues. Neither is clearly gentler than the other for everyone; tolerance is individual.
Which is right for you?
It depends on your goal (diabetes vs weight, or both), whether you prefer a daily or weekly injection, how you tolerate each, cost and coverage, and your clinician's read of your history. Our Saxenda vs Wegovy post compares the weight-management brands directly, and semaglutide vs tirzepatide covers the next step up in the class. Tracking doses and side effects in DoseLog gives your prescriber the real-world picture if you switch.
Questions people ask
What is the difference between liraglutide and semaglutide?
Both are GLP-1 receptor agonists, but liraglutide (Saxenda, Victoza) is injected once daily and semaglutide (Wegovy, Ozempic) once weekly because it is longer-acting. Semaglutide also generally produces more average weight loss.
Is semaglutide or liraglutide better for weight loss?
In trials, semaglutide at weight-management doses generally produced greater average weight loss than liraglutide. Liraglutide still works and has a long record. The best choice is the one you tolerate and can stay on, guided by your clinician.
Do liraglutide and semaglutide have the same side effects?
Broadly yes, because they are the same drug class. Nausea, diarrhea or constipation, and other gut effects are most common and cluster during dose increases. Both carry the class thyroid warning and cautions around pancreatitis and gallbladder issues.
Can you switch from liraglutide to semaglutide?
Switching within the GLP-1 class is common and is done under a prescriber's guidance, restarting titration to limit side effects. Do not switch on your own; your clinician will set the timing and starting dose based on your history.
References
- 1.Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP 1. NEJM 2021. Read on NEJM ↗
- 2.Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. SCALE. NEJM 2015. Find on PubMed ↗
- 3.Reviews comparing GLP-1 receptor agonist efficacy and tolerability. Find on PubMed ↗
- 4.Ozempic and Wegovy (semaglutide) prescribing information: dosing, adverse reactions, and warnings. View label on DailyMed ↗
- 5.Saxenda (liraglutide) prescribing information: dose escalation, adverse reactions, and warnings. View label on DailyMed ↗
This article is general education, not medical advice. DoseLog is a tracking and reflection tool. Decisions about your medication, dose, and symptoms belong with a licensed clinician.
Keep reading